CTLA4 and melanoma: In comparison to anti-CTLA-4, Pembrolizumab, Nivolumab, and anti-PD-1 antibodies which are associated with increased viability of patient with metastatic melanoma, the Ipilimumab is on first stage of wild melanoma treatment with metastatic BRAF.